Analysts Set Cambrex Corporation (CBM) Target Price at $65.67
Cambrex Corporation (NYSE:CBM) has received a consensus rating of “Hold” from the six analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $65.67.
A number of analysts recently commented on CBM shares. Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, BidaskClub downgraded Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th.
Shares of Cambrex Corporation (NYSE CBM) traded up 1.12% on Wednesday, hitting $54.05. The stock had a trading volume of 122,251 shares. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The company has a 50-day moving average of $53.13 and a 200 day moving average of $55.08. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 19.69 and a beta of 2.25.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.76. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. Cambrex Corporation’s revenue was up 13.4% on a year-over-year basis. During the same period last year, the business posted $0.68 earnings per share. On average, equities research analysts predict that Cambrex Corporation will post $3.08 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/23/analysts-set-cambrex-corporation-cbm-target-price-at-65-67.html.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total transaction of $736,680.00. Following the completion of the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at $5,852,185.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 36,000 shares of company stock valued at $2,070,960. 2.48% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in CBM. BlackRock Inc. grew its holdings in Cambrex Corporation by 156,940.2% during the first quarter. BlackRock Inc. now owns 4,002,955 shares of the biotechnology company’s stock valued at $220,363,000 after purchasing an additional 4,000,406 shares during the period. FMR LLC grew its holdings in Cambrex Corporation by 78.2% during the first quarter. FMR LLC now owns 899,086 shares of the biotechnology company’s stock valued at $49,494,000 after purchasing an additional 394,638 shares during the period. Neumeier Poma Investment Counsel LLC bought a new position in Cambrex Corporation during the first quarter valued at $16,854,000. Marshall Wace North America L.P. grew its holdings in Cambrex Corporation by 2,239.4% during the second quarter. Marshall Wace North America L.P. now owns 266,106 shares of the biotechnology company’s stock valued at $15,966,000 after purchasing an additional 254,731 shares during the period. Finally, Clearbridge Investments LLC grew its holdings in Cambrex Corporation by 34.8% during the first quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock valued at $53,463,000 after purchasing an additional 250,662 shares during the period. 98.28% of the stock is owned by institutional investors and hedge funds.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Stock Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related stocks with our FREE daily email newsletter.